Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Defne Yarar

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Molecular Biology of the Cell|November 14, 2002
Motility determinants in WASP family proteinsDefne Yarar, Joseph A D'Alessio, Robert L Jeng, et al.
The Journal of Cell Biology|March 19, 2003
Formation of filopodia-like bundles in vitro from a dendritic networkDanijela Vignjevic, Defne Yarar, Matthew D Welch, et al.
Plos Biology|March 20, 2009
Cargo and dynamin regulate clathrin-coated pit maturationDinah Loerke, Marcel Mettlen, Defne Yarar, et al.
Science Signaling|August 15, 2013
Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitorsDaniel C Kirouac, Jin Y Du, Johanna Lahdenranta, et al.
Molecular Biology of the Cell|May 16, 2014
Kinetochore genes are coordinately up-regulated in human tumors as part of a FoxM1-related cell division programPrathapan Thiru, David M Kern, Kara L McKinley, et al.
The Journal of Cell Biology|September 26, 2007
The type III effector EspF coordinates membrane trafficking by the spatiotemporal activation of two eukaryotic signaling pathwaysNeal M Alto, Andrew W Weflen, Matthew J Rardin, et al.
NPJ Systems Biology and Applications|July 21, 2017
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)Birgit Schoeberl, Art Kudla, Kristina Masson, et al.
Frontiers in Immunology|October 20, 2022
Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in miceKatarina Blagovic, Carolyne K Smith, Amritha Ramakrishnan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 29, 2022
Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8<sup>+</sup> T Cell Responses with Antitumor ActivityMatthew G Booty, Kelan A Hlavaty, Adam Stockmann, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Molecular Biology of the Cell|November 14, 2002
Motility determinants in WASP family proteinsDefne Yarar, Joseph A D'Alessio, Robert L Jeng, et al.
The Journal of Cell Biology|March 19, 2003
Formation of filopodia-like bundles in vitro from a dendritic networkDanijela Vignjevic, Defne Yarar, Matthew D Welch, et al.
Plos Biology|March 20, 2009
Cargo and dynamin regulate clathrin-coated pit maturationDinah Loerke, Marcel Mettlen, Defne Yarar, et al.
Science Signaling|August 15, 2013
Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitorsDaniel C Kirouac, Jin Y Du, Johanna Lahdenranta, et al.
Molecular Biology of the Cell|May 16, 2014
Kinetochore genes are coordinately up-regulated in human tumors as part of a FoxM1-related cell division programPrathapan Thiru, David M Kern, Kara L McKinley, et al.
The Journal of Cell Biology|September 26, 2007
The type III effector EspF coordinates membrane trafficking by the spatiotemporal activation of two eukaryotic signaling pathwaysNeal M Alto, Andrew W Weflen, Matthew J Rardin, et al.
NPJ Systems Biology and Applications|July 21, 2017
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)Birgit Schoeberl, Art Kudla, Kristina Masson, et al.
Frontiers in Immunology|October 20, 2022
Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in miceKatarina Blagovic, Carolyne K Smith, Amritha Ramakrishnan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 29, 2022
Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8<sup>+</sup> T Cell Responses with Antitumor ActivityMatthew G Booty, Kelan A Hlavaty, Adam Stockmann, et al.
Pageof 2